A more recent treatment option for patients with PNH is the C3 inhibitor pegcetacoplan, which was approved by the Food and Drug Administration (FDA) in May 2021 for the treatment of adult patients with PNH, including those switching from anti-C5 therapy (58). The gene discussed is C5; the disease is paroxysmal nocturnal hemoglobinuria.